FindTrial
Sign In

Trastuzumab-Deruxtecan (T-DXd)

DRUG2 trials

Sponsors

MedSIR, Gruppo Oncologico del Nord-Ovest

Conditions

Breast CancerColon Cancer AdenocarcinomaColon Cancer MetastaticColorectal AdenocarcinomaColorectal CancerMetastatic Breast CancerRectal AdenocarcinomaRectal Cancer, Adenocarcinoma

Phase 2

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Active, not recruitingNCT06048718
MedSIRBreast Cancer, Metastatic Breast Cancer
Start: 2024-06-05End: 2026-11-01Updated: 2026-05-08
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
RecruitingNCT07407465
Gruppo Oncologico del Nord-OvestColon Cancer Adenocarcinoma, Colon Cancer Metastatic, Colorectal Adenocarcinoma +4
Start: 2025-10-20End: 2027-10-20Target: 42Updated: 2026-02-17

Related Papers

Abstract P3-08-21: Trastuzumab-deruxtecan in HER2-low metastatic breast cancer patients with newly diagnosed or progressing brain metastases: The TUXEDO-4 phase II trial
Clinical Cancer Research2025-06-13
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases
Future Oncology2025-02-284 citations
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
2024-09-13106 citations